Loading insider details...
Beta
Latest Form 4 (May 29, 2026): Grant/Award of 8,367 EXEL shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| May 29, 2026 | EXELIXIS, INC. (EXEL) | Grant/Award | 8,367 | n/a |
| Apr 9, 2026 | Ovid Therapeutics Inc. (OVID) | Grant/Award | 17,578 | $45.0K |
| Mar 2, 2026 | Ovid Therapeutics Inc. (OVID) | Grant/Award | 65,000 | n/a |
| Nov 14, 2025 | EXELIXIS, INC. (EXEL) | Sale | 100,000 | $4.36M |
| May 30, 2025 | EXELIXIS, INC. (EXEL) | Grant/Award | 9,812 | n/a |
| May 17, 2025 | EXELIXIS, INC. (EXEL) | Exercise/Conversion | 20,634 | $407.9K |
| Mar 4, 2025 | Ovid Therapeutics Inc. (OVID) | Grant/Award | 90,000 | n/a |
| Jun 5, 2024 | EXELIXIS, INC. (EXEL) | Grant/Award | 18,838 | n/a |
| May 22, 2024 | EXELIXIS, INC. (EXEL) | Exercise/Conversion | 11,686 | $228.7K |
| May 21, 2024 | Regulus Therapeutics Inc. (RGLS) | Grant/Award | 60,000 | n/a |